|
【参考文献】
1 Cretney E, Shanker A, Yagita H, et al. TNFrelated apoptosisinducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol
Cell Biol 2006; 84(1):8798
2 Ganten TM, Koschny R, Sykora J, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer
Res 2006;12(8):26402646
3 Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3(6):673682
4 Pitti RM, Marstem SA, Ruppert S, et al. Induction of apoptosis by Apo2 Ligand, a new member of the tumor necrosis factor cytokine family.
J Bio Chem 1996; 271:1268712690
5 Pan GH, Reiner Gentz, Reinhard Ebner, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111113
6 Walczak H, Mariapia A, Pamela J, et al. TRAILR2: a novel apoptosismediating receptor for TRAIL. EMBO J 1997;16：53865397
7 Degli Esposti, Anna Ghelli, Bruna Benelli, et al. The novel receptor TRAILR4 induces NFkappa B and protects against TRAILmediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813820
8 Emery JG, Mc Donnell P, BurkeMB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Bio Chem 1998;273(23): 1436314367
9 Ferry Sandra, Laifa Hendarmin, Seiji Nakamura. Osteoprotegerin (OPG) binds with tumor necrosis factorrelated apoptosisinducing ligand (TRAIL): suppression of TRAILinduced apoptosis in ameloblastomas.
Oral Oncology 2006;42(4): 415420
10郦萍，吴雪昌.肿瘤细胞抗TRAIL凋亡诱导的分子机制.细胞生物学杂志 2006;28：153159
11 Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain containing receptor for TRAIL. Science 1997;277(5327):815818
12 Kim K, Fisher MJ, Xu SQ, et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6(2):335346
13刘军，古洵清，曾平.脉络膜肿瘤的临床观察.临床眼科杂志 2004;12(5): 428430
14 Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble APo2 lignad. J Clin Invest 1999;104(2):155162
15陈伟莉,牟旭鹏,班磊. rhTRAIL对黑色素瘤A375细胞凋亡的影响.吉林大学学报(医学版) 2008;34(4): 565568
16 Falschlehner C, Emmerich CH, Gerlach B, et al. TRAIL signalling: decisions between life and death. Int J Biochem Cell Bio 2007;39:14621475
17 Lee TJ, Jung EM, Lee JT, et al. Mithramycin A sensitizes cancer cells to TRAILmediated apoptosis by downregulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 2006;5: 27372746
18 Liu H, Jiang CC, Lavis CJ, et al. 2DeoxyDglucose enhances TRAILinduced apoptosis in human melanoma cells through XBP1mediated upregulation of TRAILR2. Mol Cancer 2009;14(8):122
19 Karasic TB, Hei TK, Ivanov VN. Disruption of IGF1R signaling increases TRAILinduced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res 2010;316(12):19942007
20 Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa, A study of 353 cases. Am J Surg Pathol 2007;31：170
21 Wissink EH, Verbrugge I, Vink SR, et al. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl2 over expressing lymphoid malignancy. Radiother Oncol 2006; 80(2):214222
22 Unnithan J, Macklis RM. TRAIL induction by radiation in lymphoma patients. Cancer Invest 2004;22(4):522525
23 Yee L, Fanale M, Dimick K, et al. A phase 1B safety and pharmacokinetic (PK) study of recombinanthumanApo2L/TRAIL in combination with rituximab in patients with low grade nonHodgkin lymphoma. J Clin
Oncol 2007;25: 8078
24 Georgakis GV，Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAILR1 and TRAILR2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin and bortezomib induced cell death.
Br J Haematol2005;130:501510
25徐玉生,王家祥,杨迪生.肿瘤坏死因子凋亡诱导配体联合顺铂对人横纹肌肉瘤细胞株凋亡的影响.中华小儿外科杂志 2006;27(12):650653
26 Komdeur R, Meijer C, van Zweeden M, et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL resistance in rhabdomyosarcoma cells. Int J Oncol 2004;25：677684 上一页 [1] [2] [3] |
